About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
  • S1P in Inflammatory Bowel Disease

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


    Sphingosine-1-phosphate (S1P) is a lipid-signaling molecule that regulates numerous biological processes through its interaction with a family of G protein–coupled receptors (S1P1 to S1P5).1 The binding of S1P to the S1P receptor subtype 1 (S1P1), expressed on the surface of lymphocytes, causes the migration of certain types of lymphocytes from lymphoid tissue into the bloodstream. An S1P gradient exists in lymphoid tissues that enables lymphocytes activated in response to antigen recognition to exit lymphoid tissues, enter circulation, migrate to intestinal tissue, and promote inflammation.2-4 S1P signaling does not affect subsets of lymphocytes that do not travel through the lymphoid tissue, and, as a result, these lymphocytes are able to remain in circulation for immune surveillance against infections and tumors.5 Lymphocytes, including B and T cells, play a critical role in regulating pro-inflammatory and anti-inflammatory activity. In inflammatory bowel disease (IBD)—Crohn’s disease and ulcerative colitis—inappropriately activated pro-inflammatory lymphocytes can leave the lymphoid tissue, migrate to the intestines, and promote chronic inflammation.2,4,6 Elevated S1P levels have been linked to IBD, and S1P has been shown to play an important role in the chronic inflammation associated with IBD.2 S1P receptor–targeting agents were successfully used in animal models of IBD. Based on preclinical evidence, targeting the S1P pathway to block S1P gradient–dependent migration of lymphocytes may help reduce chronic inflammation in these diseases.2,4

    GI, gastrointestinal; S1P, sphingosine-1-phosphate

    phosphate in Inflammatory

    st desc

    View Related Molecules


    1. Rosen H, et al. Ann Rev Biochem. 2009;78:743-768. PMID:19231986
    2. Nielson OH, et al. Trends Mol Med. 2017;23:362-374. PMID:28283249
    3. Spiegel S, Milstien S. Nat Rev Mol Cell Biol. 2003;4:397-407. PMID:12728273
    4. MSD Manual Consumer Version. https://www.msdmanuals.com/en-gb/home/immune-disorders/biology-of-the-immune-system/overview-of-the-immune-system
    5. Scott FL, et al. Br J Pharmacol. 2016;173:1778-1792. PMID:26990079
    6. Matricon J, et al. Self Nonself. 2010;1:299-309. PMID:21487504